Financial Performance - The company's total liabilities increased to 10,784,860,659.00 in 2023 from 5,429,493,543.00 in 2022, indicating a significant rise in financial obligations[4] - Net cash flow from financing activities was 3,009,342,656.00 in 2023, a substantial increase from 549,047,324.00 in 2022, reflecting higher financing activities[7] - The company's total owner's equity slightly increased to 16,294,580,817.00 in 2023 from 16,049,255,276.00 in 2022, showing stable equity growth[4] - Net cash flow from operating activities was -243,517,306.00 in 2023, a significant decline from 140,389,286.00 in 2022, indicating reduced operational cash generation[7] - The company's total assets increased to 27,079,441,476.00 in 2023 from 21,478,748,819.00 in 2022, reflecting overall growth in asset base[4] - Net cash flow from investing activities was -3,976,224,609.00 in 2023, a sharp decrease from -1,866,624,877.00 in 2022, indicating higher investment outflows[7] - The company's cash and cash equivalents at the end of the period decreased to 4,602,075,218.00 in 2023 from 4,999,501,803.00 in 2022, showing a reduction in liquid assets[7] - The company's total revenue from sales and services was 140,538,403.00 in 2023, a decrease from 375,748,843.00 in 2022, indicating a significant drop in sales[7] - The company's total equity attributable to the parent company was 16,028,587,817.00 in 2023, slightly up from 15,806,329,512.00 in 2022, showing modest growth in parent company equity[4] - The company's total comprehensive income for the period was 656,997,170.00, reflecting a strong performance in overall income generation[2] - Total equity attributable to parent company owners at the end of 2023 was RMB 2,065,117,383.00[11] - Total operating revenue for 2023 reached 6,918,724,492 yuan, a year-on-year increase of 4.61%[71] - Net profit for 2023 was 163,405,246 yuan, a significant increase from 89,388,863 yuan in 2022[80] - Revenue for the reporting period reached 6,918,724,492.00 yuan, a year-on-year increase of 4.61%[89] - Net profit attributable to shareholders of the listed company was 382,997,569.00 yuan, a year-on-year decrease of 39.12%[89] - Total assets at the end of the reporting period were 27,079,441,476.00 yuan, a year-on-year increase of 26.08%[89] - Net cash flow from operating activities was 502,407,486.00 yuan, a year-on-year decrease of 52.85%[89] - The company's monetary funds increased to 7,221,706,750.00 yuan, accounting for 26.67% of total assets, up 3.24% from the beginning of the year[88] - Short-term borrowings surged to 7,033,834,091.00 yuan, accounting for 25.97% of total assets, a significant increase of 19.01% from the beginning of the year[88] - The company's fixed assets amounted to 7,733,667,014.00 yuan, accounting for 28.56% of total assets, a decrease of 4.96% from the beginning of the year[88] - The net cash flow from operating activities in 2023 decreased by 52.85% to RMB 502.41 million compared to 2022[109] - The net cash flow from investing activities in 2023 was negative RMB 3.98 billion, a significant decrease of 113.02% compared to 2022[109] - The net cash flow from financing activities in 2023 increased by 448.10% to RMB 3.01 billion[109] - The company's financial asset investment in Meinian Gene resulted in a loss of RMB 857,940 in 2023, with the ending book value at RMB 2.13 million[103] - The company's cash and cash equivalents decreased by 2,118.56% in 2023, with a net decrease of RMB 397.43 million[109] - Net cash flow from operating activities decreased by 52.85% year-on-year, mainly due to a decrease in cash received from sales of goods[120] - Net cash flow from investing activities decreased by 113.02% year-on-year, primarily due to an increase in cash paid for purchasing financial products[120] - Net cash flow from financing activities increased by 448.1% year-on-year, mainly due to an increase in bank borrowings[120] - The company's financial assets increased significantly, with trading financial assets reaching 5,236,475,646.00 yuan, up from 1,623,975,420.00 yuan at the beginning of the period[115] - Sales expenses increased by 15.60% year-on-year to 251,802,363.00 yuan[118] - Management expenses increased by 19.44% year-on-year to 486,505,810.00 yuan[118] - R&D expenses increased by 12.31% year-on-year to 283,373,145.00 yuan[118] - The company's total revenue from the medical device industry was 6,918,724,492 yuan, with a gross profit margin of 13.70%[131] - Domestic revenue decreased by 19.20% to 917,270,373 yuan, while overseas revenue increased by 9.54% to 6,001,454,119 yuan[131] - The top 5 customers accounted for 19.17% of total annual sales, with the largest customer contributing 11.21% (775,777,250 yuan)[134] - The top 5 suppliers accounted for 26.52% of total annual procurement, with the largest supplier contributing 6.77% (304,110,477 yuan)[134] - The company's derivative investments for hedging purposes in 2023 resulted in a fair value change of RMB 2.52 million[163] - The company has a strict internal approval system and operational procedures to control risks associated with derivative investments[163] - The company completed a share repurchase plan in 2023, repurchasing 14,002,107 shares, accounting for 2.1250% of the total shares, with a total repurchase amount of RMB 314,419,803.15[186] - The total pre-tax remuneration for directors, supervisors, and senior management in 2023 was 14.6408 million yuan, with Chairman Liu Fangyi receiving the highest remuneration of 2.8805 million yuan[200] Production and Operations - The company operates five major production bases in China, located in Anhui Huaibei, Jiangxi Jiujiang, Shandong Weifang, Jiangsu Zhenjiang, and Shandong Zibo[22] - The company's products are exported to over 120 countries and regions globally, serving more than 10,000 customers[22] - The company established a new subsidiary, Jiangxi Yingcai, on July 19, 2023, with a capital contribution of RMB 43,450,000 and a 100% equity stake[42] - The company's core business is disposable gloves, which hold a significant market share both in China and globally[22] - The company focuses on innovation in automated production facilities, professional technology, and advanced manufacturing processes[22] - The company's products are widely used in medical examinations, catering services, industrial labor protection, and dental clinics[24][25] - The company's annualized production capacity for disposable non-latex gloves has reached 79 billion units, with 48 billion units for nitrile gloves and 31 billion units for PVC gloves[44] - In 2023, the company launched 24 new product projects, focusing on nitrile and PVC products, including cleanroom gloves, sterilization inspection, surgical gloves, and food-grade gloves[44] - The company has established a comprehensive production process and continuously improved the automation level of core equipment, utilizing advanced DCS systems for precise process control[44] - The company has accumulated over 10 years of production and R&D experience, integrating hardware, software, infrastructure, and proprietary technologies[44] - The company has a strong supply chain integrating raw materials, energy, production, warehousing, and logistics, connecting to a global sales and marketing network[64] - The company has a broad customer base, including large international medical product wholesalers, retailers, trading companies, and enterprises in various industries[66] - The company has invested in building a global marketing network and increased investment in online channels[70] - The company has established strategic partnerships with world-leading equipment technology companies, with production lines built after 2010 and continuously improving technical levels[61] - The company has a strong financial position, with excellent performance in 2020 and 2021 providing sufficient capital for rapid capacity expansion[63] - The company has a diverse product portfolio, including personal protective equipment, rehabilitation care products, and other medical and daily care products[49][55][57] - Personal protective equipment accounted for 89.32% of total revenue, with a year-on-year growth of 2.91%[71] - Overseas revenue increased by 9.54% to 6,001,454,119 yuan, representing 86.74% of total revenue[71] - Sales volume of disposable nitrile and PVC gloves increased by over 30% due to higher sales orders and production rates[72] - Electrode product sales and production volumes increased by over 30%, driven by new production lines[72] - Sales volume of electrode products reached 14,137.93 million pieces, a year-on-year increase of 30.04%[83] - Production volume of disposable gloves reached 6.4084 billion pieces, a year-on-year increase of 40.66%[83] - Inventory of disposable gloves increased by 69.37% to 629.7 million pieces[83] - Top five customers accounted for 19.17% of total annual sales, totaling 1,326,028,807 yuan[85] - The company's R&D expenses totaled 283,373,145.00 yuan, with an R&D expense ratio of 4.10%[91] - The company and its subsidiaries hold 240 patents, reflecting continuous enhancement of R&D capabilities[91] - Online sales of Yingke Medical gloves exceeded 2.1 billion units for the year[91] - The company's R&D personnel increased by 2.10% to 972 in 2023, with a decrease in the proportion of R&D personnel from 10.79% to 8.89%[109] - R&D investment in 2023 was RMB 283.37 million, accounting for 4.10% of operating revenue, an increase from 3.82% in 2022[109] - Several R&D projects, including ultra-strong chemical-resistant nitrile gloves and new grinding processes for auxiliary materials, have been completed and are expected to enhance product diversification and market competitiveness[99] - Ongoing R&D projects such as high-adhesion ultra-elastic PVC gloves and sulfur-free nitrile gloves aim to meet customer needs and expand sales channels[99] - The company has a global marketing network with over 400 professionals, serving more than 10,000 clients in over 120 countries and regions[123] - The company's overseas assets account for 56.26% of its net assets, with Hong Kong Yingke being the largest overseas subsidiary with assets of 9,017,639,313.00 yuan[121] - The company focuses on expanding its customer base, increasing production capacity, and developing new products to enhance its marketing network and brand awareness[124] - The company's annualized production capacity for disposable gloves increased from 75 billion to 79 billion, with nitrile gloves at 48 billion and PVC gloves at 31 billion[127] - Personal protection product revenue reached 6,179,841,631 yuan, a year-on-year increase of 2.91%[127] - The company's marketing team exceeded 400 members, participating in 40 domestic and international exhibitions in 2023[129] - The company ranked first in medical glove sales on major e-commerce platforms like Douyin and Pinduoduo in 2023[129] - The company has implemented five rounds of restricted stock incentive plans since 2017, covering approximately 1,490 key personnel[125] - The company is developing new wheelchair and hot/cold compress products while upgrading existing production lines[128] - Global disposable glove market size grew from 440.9 billion in 2017 to 622.5 billion in 2022, with a CAGR of 8.2%[138] - In 2023, the industry's downstream inventory is nearing the end of digestion, and supply-demand dynamics are gradually stabilizing[138] - The company's subsidiary, Shandong Yingke, reported total assets of 5,890,864,094.00 RMB and net profit of 86,658,661.00 RMB[137] - Jiangsu Yingke, another subsidiary, reported total assets of 1,595,108,209.00 RMB and net profit of 89,596,991.00 RMB[137] - Anhui Yingke, a subsidiary, reported total assets of 8,743,167,443.00 RMB and net profit of 63,470,612.00 RMB[137] - Hong Kong Yingke, a subsidiary, reported total assets of 9,879,748,466.00 RMB and net profit of 170,998,223.00 RMB[137] - Jiangxi Yingke, a subsidiary, reported total assets of 3,815,089,843.00 RMB and net profit of 111,208,348.00 RMB[137] - Yingke Medical International, a subsidiary, reported total assets of 9,378,824,665.00 RMB and net profit of 252,073,483.00 RMB[137] - The company established a new subsidiary, Jiangxi Yingcai, to enhance market competitiveness[137] - The company's strategy includes implementing global strategies to consolidate its leading industry position[142] - The company plans to expand its global marketing network, with existing centers in the US, Canada, Germany, Japan, and Malaysia, and plans to establish new centers in the Middle East and South America to grow its global customer base[154] - The company has a professional marketing team of over 400 members globally and plans to recruit more talent to strengthen its global marketing efforts and penetrate the disposable glove market further[154] - The company is enhancing automation and AI in production facilities to maintain its technological advantage[154] - The company is advancing the construction of the Yingke Medical Intelligent Medical Device R&D and Marketing Technology Park in Zibo, Shandong Province[155] - The company is improving production efficiency by adopting more advanced production processes, automated hardware, and intelligent control systems[155] - The company's export business accounts for over 80% of total revenue, with some raw materials settled in USD. The company uses financial derivatives like forward contracts to manage exchange rate risks[156] - The company has implemented measures to ensure the stability of its supply chain, including self-production of raw materials, optimized procurement, and process improvements[156] - The company collaborates with Qingdao University of Science and Technology to develop innovative materials and new formulations for disposable gloves[162] - The company has completed 8 self-developed and self-produced projects, covering 9 major product categories and over 60 product series as of June 30, 2023[167] - The company has built a third-generation nitrile double-mold fully automated production line with independent intellectual property rights, which has higher production efficiency and lower energy consumption[168] - The company plans to use between RMB 100 million and RMB 200 million to repurchase shares, with a maximum repurchase price of RMB 33.11 per share, and has already repurchased 4,504,300 shares, accounting for 0.6866% of the total shares[169] - The company plans to further strengthen the application of automation and artificial intelligence in production facilities, focusing on online visual inspection and automated packaging[176] - The company will continue to increase R&D investment to optimize processes and implement more precise control over production, maintaining its technological advantage[176] - The company plans to deepen vertical integration of the industrial value chain through selective strategic investments and acquisitions, focusing on upstream raw materials, equipment, and component suppliers[178] - The company expects the demand for disposable gloves to continue to grow steadily each year due to increased health protection awareness and government regulations[178] - The company will reasonably advance the construction of base projects in Anqing, Anhui, and Qingzhou, Shandong, and will promote natural latex glove and nitrile glove projects as appropriate[178] - The company has established a third-generation nitrile double-mold fully automated production line, which provides a cost advantage due to higher efficiency and lower energy consumption[168] - The company has repurchased shares worth RMB 100,015,581, with the highest transaction price at RMB 23.75 per share and the lowest at RMB 21.35 per share[169] - The company faces potential risks due to increased competition in the disposable glove market, with prices expected to remain relatively low, impacting future performance[192] - The company is affected by U.S. tariffs on disposable nitrile gloves, with 7.5% on medical-grade and 25% on industrial-grade, and Japan's 3.1% tariff on PVC gloves starting April 2024[193] - The company is committed to improving corporate governance, enhancing transparency, and strengthening investor relations to build long-term value[194] - The company has an independent financial management system, with no funds or assets being misused by controlling shareholders or related parties[196] - The total number of shares held by directors, supervisors, and senior management at the end of the period was 232,545,327 shares, a decrease of 268,530 shares due to restricted stock repurchase and cancellation[198] - The company completed the repurchase and cancellation of restricted shares on November 16, 2023, resulting in a reduction of 96,000 shares for Chen Qiong, 76,800 shares for Yu Haisheng, 67,800 shares for Li Bin, 14,430 shares for Feng Jie, 6,210 shares for Xu Juan, and 7,290 shares for Zhai Wenning[198] - Feng Jie, the CFO, was appointed as the Board Secretary on February 27, 2024, and has been serving as

英科医疗科技股份有限公司 2023 年度监事会工作报告 2023年，英科医疗科技股份有限公司（以下简称"公司"）监事 会严格按照《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《英科医疗科技 股份有限公司章程》（以下简称"《公司章程》"）、《监事会议事规 则》等有关法律、法规的要求，以维护公司利益、股东权益为原则， 认真履行职责。公司监事对公司经营活动、财务状况、重大决策以及 董事、高级管理人员履行职责情况等方面实施了有效监督，为公司规 范运作、完善和提升治理水平有效发挥了职能。 监事会认为公司董事会成员及公司高级管理人员忠于职守，全面 落实了各项工作，在2023年取得了良好的业绩，经营中未出现任何违 规操作或损害股东利益的行为。 现将监事会在报告期内的工作情况报告如下： 一、2023年度监事会会议召开情况 公司2023年度共召开7次监事会会议，监事会会议的召开、决议 内容的签署以及监事权利的行使符合《公司法》《公司章程》《监事会 议事规则》的相关规定。会议召开的具体情况如下： 1 1、第三届监事会第十一次会议于2023年1月16日在公司会议室以 通讯 ...

英科医疗科技股份有限公司 董事会审计委员会对会计师事务所2023年度履职情 况评估及履行监督职责情况的报告 根据《中华人民共和国公司法》《上市公司治理准则》《国有企 业、上市公司选聘会计师事务所管理办法》《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》等法律法规、 规范性文件和英科医疗科技股份有限公司（以下简称"公司"）的《英 科医疗科技股份有限公司章程》（以下简称"《公司章程》"）《董 事会专门委员会工作制度》等公司制度的规定和要求，董事会审计委 员会本着勤勉尽责的原则，恪尽职守，认真履职。现将董事会审计委 员会对会计师事务所 2023 年度履职情况评估及履行监督职责的情况 汇报如下： 一、2023 年年审会计师事务所基本情况 （一）会计师事务所基本情况 普华永道中天会计师事务所（特殊普通合伙）（以下简称"普华 永道中天"）前身为 1993 年 3 月 28 日成立的普华大华会计师事务 所，经批准于 2000 年 6 月更名为普华永道中天会计师事务所有限公 司；经 2012 年 12 月 24 日财政部财会函[2012]52 号批准，于 2013 年 1 月 18 日转制为普华永 ...

| 01 | | 02 | | 03 | | 04 | | 05 | | 06 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 关于 | | 低碳环保 | | 匠心制造 | | 人才为先 | | 传递温暖 | | 完善治理 | | | 英科 国疗 | | 绿色前行 | | 坚守品质 | | 携手共赢 | | 健康关怀 | | 恪守责任 | | | 2023年大事记 | 06 | 绿色生产管理 | 13 | 创新驱动产品 | 23 | 保障员工权益 | 32 | 坚持行业共建 | 39 | 完善公司治理 | 46 | | 我们的业务 | 07 | 应对气候变化 | 16 | 严控质量管理 | 25 | 助力员工成长 | 34 | 传播健康知识 | 40 | 严守廉洁道德 | 48 | | ESG管治 | 09 | 资源高效利用 | 19 | 保障责任供应 | 28 | 守护职业安全 | 35 | 强健社会责任 41 | | 维护信息安全 | 50 | | | | 强化污染治理 | 20 | 打造优质服 ...

证券代码：300677 证券简称：英科医疗 公告编号：2024-031 英科医疗科技股份有限公司 第三届董事会第二十一次（定期）会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 英科医疗科技股份有限公司（以下简称"公司"）第三届董事会 第二十一次（定期）会议于 2024 年 4 月 23 日以现场会议结合通讯方 式召开，会议通知已于 2024 年 4 月 12 日以专人送达、电子邮件、传 真、电话或即时通讯工具等形式向全体董事发出。会议由董事长刘方 毅先生召集并主持，本次会议应出席董事 7 名，实际出席会议董事 7 名，公司部分监事和高级管理人员列席了本次会议。会议的召集和召 开符合《中华人民共和国公司法》《英科医疗股份有限公司章程》（以 下简称"《公司章程》"）的有关规定。 二、董事会会议审议情况 1、审议通过《关于<2023年度董事会工作报告>的议案》 董事会对公司主营业务、资产及负债、投资状况、未来发展的展 望、董事会及专门委员会会议召开情况分别进行了认真梳理、研究与 分析，审议通过了《2023 年度董事会工作报告》，具体内 ...

英科医疗科技股份有限公司 2023 年度财务报表及审计报告 英科医疗科技股份有限公司 2023 年度财务报表及审计报告 | 内容 | 页码 | | --- | --- | | 审计报告 | 1 - 5 | | 2023 年度财务报表 | | | 合并及公司资产负债表 | 1 - 2 | | 合并及公司利润表 | 3 | | 合并及公司现金流量表 | 4 | | 合并股东权益变动表 | 5 - 6 | | 公司股东权益变动表 | 7 - 8 | | 财务报表附注 | 9 - 134 | | 补充资料 | 1 - 2 | 普华永道 审计报告 普华永道中天审字(2024)第 10151 号 (第一页,共五页) 英科医疗科技股份有限公司全体股东: 一、审计意见 二、形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计报告的"注册 会计师对财务报表审计的责任"部分进一步阐述了我们在这些准则下的责任。我们相 信,我们获取的审计证据是充分、适当的,为发表审计意见提供了基础。 按照中国注册会计师职业道德守则,我们独立于英科医疗公司,并履行了职业 道德方面的其他责任。 三、关键审计事项 关键审计事项是我 ...

英科医疗科技股份有限公司 2023 年度非经营性资金占用及其他关联资金往来情况汇总表 单位： 人民币元 | 非经营性资金占用 | 资金占 用方名 | 占用方与上市 公司的关联关 | 上市公司核 算的会计科 | 2023 年期初占 | 2023 | 年度占用累计 | 2023 年度偿还累 | 2023 | 年度占用 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 用资金余额 | 发生金额（不含利 | | 计发生金额 | | 资金余额 | 原因 | | | | 称 | 系 | 目 | | | 息） | | | | | | | 控股股东、实际控 制人及其附属企业 | | | | | | 不适用 | | | | | | | 小 计 | | | | | | 不适用 | | | | | | | 前控股股东、实际 控制人及其附属企 | | | | | | 不适用 | | | | | | | 业 | | | | | | | | | | | | | 小 计 | | | | | ...

英科医疗科技股份有限公司 2023 年度独立董事述职报告 （吴晓辉） 尊敬的各位股东及股东代表： 本人吴晓辉，作为英科医疗科技股份有限公司（以下简称"公司"） 第三届董事会独立董事，严格按照《中华人民共和国公司法》（以下 简称"《公司法》"）、《上市公司独立董事管理办法》《深圳证券交易所 创业板股票上市规则》等有关法律、法规以及《英科医疗科技股份有 限公司章程》（以下简称"《公司章程》"）、《独立董事工作细则》 等公司制度的规定，在 2023 年度工作中，定期了解公司的财务状况 和经营情况，忠实履行独立董事的相关职责，积极出席公司召开的相 关会议，认真审阅各项议案及相关会议材料，对董事会的相关事项发 表意见，充分发挥独立董事的作用，努力维护公司和全体股东特别是 中小股东的合法权益。根据《深圳证券交易所上市公司自律监管指引 第 2 号——创业板上市公司规范运作》等有关规定的要求，现将 2023 年度本人履行独立董事的职责情况报告如下： 一、基本情况 （一）独立董事工作履历、专业背景及兼职情况 本人吴晓辉，1971 年出生，学士学历，注册会计师。1993 年获 得上海理工大学学士学位，1994 年 4 月至 19 ...

英科医疗科技股份有限公司 2023 年度控股股东及其他关联方占用资金情况专项报告 普华永道 关于英科医疗科技股份有限公司 控股股东及其他关联方占用资金情况专项报告 普华永道中天特审字(2024)第1748号 (第一页,共二页) 英科医疗科技股份有限公司董事会: 我们审计了英科医疗科技股份有限公司(以下简称"英科医疗公司")2023年12月 31 日的合并及公司资产负债表、2023年度合并及公司利润表、合并及公司现金流量表、 合并及公司股东权益变动表和财务报表附注(以下合称"财务报表"),并于 2024年 4 月 23 日出具了报告号为普华永道中天审字(2024)第 10151 号的无保留意见审计报告。 财务报表的编制和公允列报是英科医疗公司管理层的责任,我们的责任是在按照中国 注册会计师审计准则执行审计工作的基础上对财务报表整体发表审计意见。 在对上述财务报表执行审计的基础上,我们对后附的截至 2023年 12 月 31 日止 年度英科医疗公司控股股东及其他关联方非经营性资金占用及其他关联资金往来情况 汇总表(以下简称"情况表")执行了有限保证的鉴证业务。 根据中国证券监督管理委员会《上市公司监管指引第 8 ...

证券代码：300677 证券简称：英科医疗 公告编号：2024-032 英科医疗科技股份有限公司 第三届监事会第十九次（定期）会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 英科医疗科技股份有限公司（以下简称"公司"）第三届监事会 第十九次（定期）会议于 2024 年 4 月 23 日在公司会议室以现场会议 结合通讯方式召开，会议通知已于 2024 年 4 月 12 日以专人送达、电 子邮件、传真、电话或即时通讯工具等形式向全体监事发出。会议由 公司监事会主席唐烨先生召集和主持，本次会议应出席监事 3 名，实 际出席会议监事 3 名。会议的召集和召开符合《中华人民共和国公司 法》《英科医疗股份有限公司章程》（以下简称"《公司章程》"）的有 关规定。 二、监事会会议审议情况 1、审议通过《关于<2023年度监事会工作报告>的议案》 2023 年度，公司监事会履行了监事会的监督职权和职责，对公司 经营活动、财务状况、关联交易等方面实施了有效监督，保障了公司、 股东及员工的合法权益，具体内容请详见同日登载于巨潮资讯网 （www.cni ...